GI Oncology
News
Tivantinib Shows Modest Benefit in Relapsed Liver Cancer
Major Finding: Median time to progression, the primary end point, was 6.9 weeks for patients randomized to tivantinib, compared with 6.0 weeks for...
News
Brivanib Can't Match Sorafenib for Advanced Liver Cancer
Major Finding: Comparisons of the median overall survival between brivanib- and sorafenib-treated patients showed an overall hazard ratio of 1.07...
News
Earlier End-of-Life Talks Deter Aggressive Care of Terminal Cancer Patients
Major Finding: Chemotherapy in the last 2 weeks of life was 59% less likely, acute care in the last 30 days was 57% less likely, and ICU care in...
News
Antivirals Linked to Lower Risk of Liver Cancer Return
Major Finding: The cumulative 6-year rate of hepatocellular carcinoma recurrence was 45.6% for patients taking nucleoside analogues and 54.6% for...
News
Most Gastric Tumors Handled Best With Laparoscopy
News
Evidence Mounts for Aspirin's Anticancer Attributes
Major Finding: In a review of data from 51 studies, daily aspirin use reduced cancer deaths by 15% compared with no daily aspirin use, and reduced...
From the AGA Journals
Management of Zollinger-Ellison May Depend on Presence of Tumors
News
Evidence Mounts for Continuing Bevacizumab After Colorectal Cancer Progresses
Major Finding: Median progression-free survival was 4.9 months with second-line chemotherapy alone vs. 6.7 months with the addition of bevacizumab...
News
FDA Approves Aflibercept for Advanced Colorectal Cancer
News
Gefitinib Palliates Advanced Esophageal Cancer
Major Finding: Median overall survival was 3.73 months with gefitinib vs. 3.60 months with placebo (P = .285).Data Source: Data are from a phase...